No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
4cc of lidocaïne® |
- |
- |
- |
- |
[1] 149 |
2 |
9060x |
- |
- |
- |
- |
[2] 13, 149 |
3 |
Baclofen |
Baclofen |
D00241 |
[2] GABBR1, GABBR2 |
[7] Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
[5] 2, 10, 13, 18, 149 |
4 |
Balance |
Isoxaflutole |
- |
- |
- |
[8] 5, 6, 13, 18, 81, 113, 149, 299 |
5 |
Botox |
Botulinum toxin type a |
D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[4] 6, 13, 149, 226 |
6 |
Botulinum toxin a |
Botulinum toxin type a |
D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[4] 13, 51, 149, 226 |
7 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[10] 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
8 |
Brivaracetam |
Brivaracetam |
D08879 |
[1] SV2A |
[1] ECM-receptor interaction |
[2] 149, 309 |
9 |
Edonerpic |
Edonerpic |
- |
- |
- |
[1] 149 |
10 |
Hc-58 |
- |
- |
- |
- |
[1] 149 |
11 |
Lacosamide |
Lacosamide |
D07299 |
[2] SCN3A, SCN9A |
[1] Taste transduction |
[3] 2, 46, 149 |
12 |
Medicinal air |
- |
- |
- |
- |
[1] 149 |
13 |
Meopa |
- |
- |
- |
- |
[1] 149 |
14 |
Oxybate |
Gamma-hydroxybutyric acid |
- |
- |
- |
[3] 6, 120, 149 |
15 |
Padsevonil |
Padsevonil |
- |
- |
- |
[1] 149 |
16 |
Placebo |
- |
- |
- |
- |
[20] 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
17 |
Sodium oxybate |
Sodium oxybate |
D05866 |
- |
- |
[3] 6, 120, 149 |
18 |
Spm927 |
- |
- |
- |
- |
[1] 149 |
19 |
T-817ma |
- |
- |
- |
- |
[1] 149 |
20 |
Time delay treatment of botulinum toxin |
- |
- |
- |
- |
[1] 149 |
21 |
Triheptanoin |
Triheptanoin |
D11465 |
- |
- |
[10] 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |
22 |
Ucb 34714 |
- |
- |
- |
- |
[1] 149 |